Kantar Health, Sunovion Release Results for SBC Study

New research by Kantar Health and Sunovion Pharmaceuticals suggests that high patient-reported adherence to sodium channel blocker (SBC) epilepsy drug treatments resulted in statistically and clinically meaningful improvements in health-related quality of life (HRQoL). The findings will be detailed in a podium presentation at ISPOR 2018 on May 22, 2018.

New York, NY, May 21, 2018 --(PR.com)-- High Adherence to Sodium Channel Blocker Anti-Epileptic DRUG Treatments Suggests Improvements to Patient HRQoL, Kantar Health Study Finds

Results to be Presented at ISPOR 2018

New real-world research by Kantar Health and Sunovion Pharmaceuticals Inc. (Sunovion) suggests that high patient-reported adherence to sodium channel blocker (SCB) epilepsy drug treatments resulted in statistically and clinically meaningful improvements in health-related quality of life (HRQoL). The findings will be detailed in a podium presentation on May 22, 2018 at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 meeting in Baltimore.

"While it is known that higher adherence is associated with better health-related quality of life, there's limited research on the benefits of adherence to SCB antiepileptic drug treatments among patients with epilepsy," said study researcher Lulu K. Lee, PhD, Director of Health Outcomes Research for Kantar Health, a global leader in healthcare market research and consulting. "What's unique about this real-world assessment of epilepsy patients on sodium channel blockers is that it may be the first study focused on examining the association between adherence and patient-reported outcomes within this class of medicines."

In the study, conducted jointly between Kantar Health's Dr. Lulu Lee and Sunovion's Dr. Krithika Rajagopalan, data from Kantar Health's 2017 U.S. National Health and Wellness Survey (NHWS) - a nationally representative, self-administered, internet-based survey of adults - were analyzed, and respondents with a self-reported diagnosis of epilepsy who were taking an SCB medicine for epilepsy were categorized into low/medium adherence and high adherence groups based on Morisky Medication Adherence scores. The study - "The Association between Anti-Epileptic Drugs Adherence to Sodium Channel Blockers and Health-Related Quality of Life: Analysis of U.S. Survey Data from Patients with Epilepsy" - is a finalist for an ISPOR Research Podium Presentation Award.

In addition to this podium presentation, Kantar Health will also be presenting several research posters, including:

Diabetes Medication Adherence and Changes in Healthcare Resource Use Over Time - In this longitudinal NHWS poster Kantar Health examined how adherence influences healthcare resource utilization (HCRU) over time. The research finds that for diabetes patients, high adherence is associated with fewer ER visits and hospitalizations.
CHI-Square Automatic Interaction Detection (CHAID) Analysis: Understanding and Informing Treatment Choice of Second-line Metastatic Urothelial Cancer - In this Chi-square Automatic Interaction Detector (CHAID) poster, which uses bladder cancer physician chart data, Kantar Health details how the use of CHAID allows for the visualization of the relationship between physicians and patients and how these characteristics affect treatment choices.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.
Contact Information:
Kantar Health
Gary Gatyas
484-442-1409
Contact via Email
www.kantarhealth.com
Mobile: 215-820-6621

Online Version of Press Release:
You can read the online version of this press release at: https://www.pr.com/press-release/754182